GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (NAS:CLLS) » Definitions » Shiller PE Ratio

Cellectis (Cellectis) Shiller PE Ratio : (As of Apr. 29, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cellectis Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cellectis Shiller PE Ratio Historical Data

The historical data trend for Cellectis's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Shiller PE Ratio Chart

Cellectis Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cellectis Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cellectis's Shiller PE Ratio

For the Biotechnology subindustry, Cellectis's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellectis's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectis's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cellectis's Shiller PE Ratio falls into.



Cellectis Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Cellectis's E10 for the quarter that ended in Sep. 2023 is calculated as:

For example, Cellectis's adjusted earnings per share data for the three months ended in Sep. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.31/118.2600*118.2600
=-0.310

Current CPI (Sep. 2023) = 118.2600.

Cellectis Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201212 0.000 99.100 0.000
201306 -1.119 99.700 -1.327
201312 0.000 99.800 0.000
201406 0.000 100.180 0.000
201412 0.000 99.860 0.000
201503 0.206 100.170 0.243
201506 -0.707 100.440 -0.832
201509 -0.405 99.950 -0.479
201512 0.251 100.040 0.297
201603 -0.952 100.020 -1.126
201606 -0.200 100.630 -0.235
201609 -0.400 100.340 -0.471
201612 -0.368 100.650 -0.432
201703 -0.560 101.170 -0.655
201706 -0.750 101.320 -0.875
201709 -0.730 101.330 -0.852
201712 -0.760 101.850 -0.882
201803 -0.710 102.750 -0.817
201806 -0.170 103.370 -0.194
201809 -0.540 103.560 -0.617
201812 -0.530 103.470 -0.606
201903 -0.360 103.890 -0.410
201906 -0.788 104.580 -0.891
201909 -0.380 104.500 -0.430
201912 -0.880 104.980 -0.991
202003 0.470 104.590 0.531
202006 -0.760 104.790 -0.858
202009 -0.710 104.550 -0.803
202012 -0.950 104.960 -1.070
202103 -0.280 105.750 -0.313
202106 -0.880 106.340 -0.979
202109 -0.820 106.810 -0.908
202112 -0.950 107.850 -1.042
202203 -0.700 110.490 -0.749
202206 -0.420 112.550 -0.441
202209 -0.630 112.740 -0.661
202212 -0.590 114.160 -0.611
202303 -0.580 116.790 -0.587
202306 -0.190 117.650 -0.191
202309 -0.310 118.260 -0.310

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cellectis  (NAS:CLLS) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Cellectis Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Cellectis's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellectis (Cellectis) Business Description

Traded in Other Exchanges
Address
8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

Cellectis (Cellectis) Headlines

From GuruFocus

Cellectis Announces Launch of Follow-On Offering

By Stock market mentor Stock market mentor 02-02-2023